However many patients either do not respond to antibiotics, or lose response to individual antibiotics. Herein we describe two cases of refractory chronic pouchitis treated successfully with oral administration of ertapenem, a carbapenem antibiotic that is minimally absorbed from the GI tract when given orally.
The first case was a 62 year old man with chronic pouchitis initially responsive to antibiotics. He previously lost response to oral antibiotics which included tetracycline, sulfamethoxazole-trimethoprim, ciprofloxacin, metronidazole, minocycline and rifaximin. His pouchitis had also been treated with, and had inadequate responses to, methotrexate, adalimumab, certolizumab and infliximab. Despite this he reported up to 20 loose stool per day, abdominal cramps and rectal bleeding, and a pouchoscopy revealed severe inflammation of the ileum and pouch (Fig. 1A ). CMV and Clostridium difficile were negative. Incidentally, he was treated with intravenous ertapenem by the ID team for a perianal abscess, with dramatic improvement in his pouchitis symptoms. Follow-up pouchoscopy confirmed endoscopic healing in his pouch (Fig. 1B) . Ertapenem is only available as a powder for reconstitution for IV/IM administration, as it is poorly absorbed from the GI tract. In view of this he was instructed to reconstitute one vial (1 g) of ertapenem powder in water for oral administration by his gastroenterologist each day. He has remained in remission since then (6 months).
The second case is a 43 year old man with chronic pouchitis and multiple pouchoscopies who demonstrated ulcers and active inflammation in the pouch. He failed to respond to VSL #3, ciprofloxacin, doxycycline, metronidazole, sulfamethoxazole-trimethoprim, infliximab and adalimumab and natalizumab. Due to our success with the first patient, we initiated oral ertapenem (1 g/day) also. He also experienced clinical response, and a subsequent pouchoscopy demonstrated improved endoscopic appearance of the pouch. He remained in clinical remission at 3 months follow-up.
Ertapenem (Invanz, Merck) is FDA-approved for intravenous (IV) or intramuscular (IM) use for the "treatment of moderate to severe infections caused by susceptible bacteria". 3 It is supplied as a lyophilized powder in a vial, which requires reconstitution for IV/IM administration. Pre-clinical studies demonstrated poor oral bioavailability in rodents (b 6%), reflecting poor oral absorption from the GI tract.
3 Oral administration of 500 mg/kg ertapenem in mice (35-times the dose used in these cases) produced no adverse effects over 7 days in toxicology studies.
3 This combination of retention in the GI tract and bactericidal properties is favorable in agents used to treat the dysbiosis seen in pouchitis. 2 In conclusion, these two cases of refractory pouchitis exhibited clinical and endoscopic remission after a course of orally administered ertapenem. This agent could be considered in similar cases of refractory pouchitis, although randomized clinical studies would be required to determine its safety and efficacy in this patient population.
